Boehringer to get Zantac rights as part of J&J-Pfizer deal

10/12/2006 | Yahoo!

Johnson & Johnson and Pfizer say they will sell U.S. marketing rights for the heartburn drug Zantac to Boehringer Ingelheim Pharmaceuticals for $509.5 million as part of J&J's planned acquisition of Pfizer's consumer health business. The sale is intended to facilitate Federal Trade Commission approval of the $16.6 billion J&J-Pfizer deal.

View Full Article in:

Yahoo!

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA